Among adults with chronic rhinosinusitis with nasal polyps who endured endoscopic sinus surgery, those with severe vs. mild ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe ...

Type 2 CRSwNP is linked to worse health-related quality of life, with higher rates of smell loss and rhinorrhea emerging as ...

According to the ACTIONS study, 39% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) faced overexposure to ...

In patients with chronic rhinosinusitis with nasal polyps, factors including baseline antibiotic use and asthma impacted the ...

Similarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo. Depemokimab, a monoclonal antibody targeting ...

The approval in adolescent patients with CRSwNP was also supported by pharmacokinetic data from adult and pediatric patients aged 12 years and older with moderate to severe asthma and adult ...

The study cohort included 699 patients with CRSwNP—247 with glucocorticoid insensitivity and 452 with glucocorticoid sensitivity—who received care for their condition between 2010 and 2019.

The prevalences of allergic rhinitis and asthma were more common in the CRSwNP group compared with the CRSsNP group (P < .05 for both), at 43.6% vs 19.8% and 48.2% vs 15.1%, respectively, but ...